Back to search results

Respiratory Muscle Training for Obesity and Brain Health

This study is looking at whether special breathing exercises, called inspiratory muscle strength training, can improve brain health and immune function in adults with obesity. Obesity can affect how well your brain works and your immune system. Researchers want to see if strengthening your breathing muscles with a device can help. You might be able to join if you are between 18 and 45 years old, have a Body Mass Index (BMI) of 30 or higher, and meet certain waist circumference requirements. The study will measure changes in blood flow to your brain to see if the training is successful. The current status of this study is unclear, and it plans to enroll 30 participants.

Study design
This interventional study plans to enroll 30 participants to test high-intensity inspiratory muscle strength training against a low-intensity version.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for changes in brain blood flow reactivity for up to 9 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07406295

Respiratory Muscle Training to Improve Cerebrovascular and Immune Function

Recruiting
NAAges 18–45InterventionalBasic science
Florida State University
~30 participants
Updated 2026-06-26 on ClinicalTrials.gov
What's tested:High intensity inspiratory muscle strength trainingLow intensity

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in middle cerebral artery blood velocity reactivity to hypercapnia
Measured over Up to 9 weeks

Conditions

Obesity
Cerebrovascular Function
Immune Cells Activity

Explore related trials

Obesity

Where it's being run

1 sites across 1 states
Florida1

Study leadership

  • Joseph C Watso, PhD · PRINCIPAL_INVESTIGATOR · Florida State University

Who to contact

Thomas Bissen, MS
[email protected]
9522121833
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Body mass index greater than or equal to 30 kg/m2
Waist circumference greater or equal to 88 cm for females and greater than or equal to 102 cm for males

Exclusion

Not weight stable (\<5% change in body mass over the past six months)
Overt cardiovascular, neurological, renal, liver, and/or metabolic illness (e.g., diabetes mellitus)
Current, or history of uncontrolled, Stage 2 hypertension (blood pressure \>140 / 90 mmHg; anti-hypertensive medications are permitted)
Diagnosed obstructive sleep apnea
Previous bariatric surgery
Diagnosis or signs (e.g., values below the lower limit of normal) of overt airway disease(s)
Current or recent (regular use within the past 6 months) use of tobacco or nicotine products (e.g., cigarettes, vaping)
Pregnant (self-reported and confirmed via urine pregnancy test), lactating (self-reported), or post-menopausal (self-reported) females
Prisoners
Patients who have undergone recent abdominal surgery and those with abdominal hernia.
Asthma patients who have a very low symptom perception and suffer from frequent, severe exacerbations or with an abnormally low perception of dyspnea.
If a patient is suffering from a ruptured eardrum or any other condition of the ear.
Patients with marked elevated left ventricular end-diastolic volume and pressure.
Patients with worsening heart failure signs and symptoms after training. If an individual is suffering from a cold, sinusitis or respiratory tract infection, it is advised that they do not use the POWERbreathe device.

What this trial measures

  • Change in middle cerebral artery blood velocity reactivity to hypercapniaUp to 9 weeks

    Middle cerebral artery blood velocity will be measured via transcranial Doppler ultrasound